The OncoArray Consortium, an endeavor involving 550 researchers from 6 continents, identified new target genes that may allow for better definition of the pathways and mechanisms underlying breast cancer susceptibility.
Breast Cancer Targets
In this interview with Mary Daly, MD, PhD, she gives an overview of multigene panel testing for breast cancer, and how they can be used by clinicians to interpret risk and treat accordingly.
Tumor Infiltrating Lymphocytes May be Predictive in African-American Women with Triple-Negative Breast Cancer
For African-American women with triple-negative breast cancer, high levels of tumor infiltrating lymphocytes may mean a better prognosis.
Researchers have developed nanoparticles that can carry targeted therapy to tumors with bone metastases, which may have particular benefit for breast cancer patients.
Dr. Judy Garber offers further perspective on the topic of PARP inhibitors in triple-negative breast cancer, which she presented in an education session at 2017 ESMO.
Moderate- to high-intensity exercise may lead to an acute increase in levels of epinephrine, which can reduce breast cancer cell viability and tumor growth via activation of the Hippo signaling pathway.
The FDA has approved abemaciclib for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer that has progressed after failure of initial therapy.
A recent analysis of 360 primary breast cancer genomes has identified some potentially important cancer-driving mutations found within noncoding genomic regions.
Comprehensive sequencing for all breast cancer genes may provide complete relevant genetic information for Ashkenazi Jewish patients.
Researchers have discovered new associations between breast and ovarian cancer and genes that had not been previously detected, and which may help guide treatment decisions in the future.